These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 36099411)
81. Differences across sexes on head-twitch behavior and 5-HT Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476 [TBL] [Abstract][Full Text] [Related]
82. Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging. T L'Estrade E; Hansen HD; Erlandsson M; Ohlsson TG; Knudsen GM; Herth MM ACS Chem Neurosci; 2018 Jun; 9(6):1226-1229. PubMed ID: 29763291 [TBL] [Abstract][Full Text] [Related]
83. Setup of a Serotonin 2A Receptor (5-HT2AR) Bioassay: Demonstration of Its Applicability To Functionally Characterize Hallucinogenic New Psychoactive Substances and an Explanation Why 5-HT2AR Bioassays Are Not Suited for Universal Activity-Based Screening of Biofluids for New Psychoactive Substances. Pottie E; Cannaert A; Van Uytfanghe K; Stove CP Anal Chem; 2019 Dec; 91(24):15444-15452. PubMed ID: 31725281 [TBL] [Abstract][Full Text] [Related]
84. MAGI proteins can differentially regulate the signaling pathways of 5-HT Hammad MM; Dunn HA; Ferguson SSG Cell Signal; 2018 Jul; 47():109-121. PubMed ID: 29625175 [TBL] [Abstract][Full Text] [Related]
85. Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Gresch PJ; Smith RL; Barrett RJ; Sanders-Bush E Neuropsychopharmacology; 2005 Sep; 30(9):1693-702. PubMed ID: 15756304 [TBL] [Abstract][Full Text] [Related]
86. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661 [TBL] [Abstract][Full Text] [Related]
87. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Moreno JL; Holloway T; Albizu L; Sealfon SC; González-Maeso J Neurosci Lett; 2011 Apr; 493(3):76-9. PubMed ID: 21276828 [TBL] [Abstract][Full Text] [Related]
88. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A Elife; 2018 Oct; 7():. PubMed ID: 30355445 [TBL] [Abstract][Full Text] [Related]
91. Lysergic acid diethylamide induces behavioral changes in Caenorhabditis elegans. Ornelas IM; Carrilho BS; Ventura MAVC; Domith I; de V Silveira CM; Dos Santos VF; Delou JM; Moll F; Pereira HMG; Junqueira M; Aguilaniu H; Rehen S Neurosci Lett; 2024 Aug; 837():137903. PubMed ID: 39025433 [TBL] [Abstract][Full Text] [Related]
92. Differential signaling signatures evoked by DOI versus lisuride stimulation of the 5-HT Banerjee AA; Vaidya VA Biochem Biophys Res Commun; 2020 Oct; 531(4):609-614. PubMed ID: 32814630 [TBL] [Abstract][Full Text] [Related]
93. Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice. Moreno JL; Holloway T; Umali A; Rayannavar V; Sealfon SC; González-Maeso J Psychopharmacology (Berl); 2013 Jan; 225(1):217-26. PubMed ID: 22842765 [TBL] [Abstract][Full Text] [Related]
94. Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats. Popik P; Krawczyk M; Kuziak A; Bugno R; Hogendorf A; Staroń J; Nikiforuk A J Psychopharmacol; 2019 Nov; 33(11):1447-1455. PubMed ID: 31452444 [TBL] [Abstract][Full Text] [Related]
95. Psychedelics as Medicines: An Emerging New Paradigm. Nichols DE; Johnson MW; Nichols CD Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026 [TBL] [Abstract][Full Text] [Related]
96. A mechanistic model of the neural entropy increase elicited by psychedelic drugs. Herzog R; Mediano PAM; Rosas FE; Carhart-Harris R; Perl YS; Tagliazucchi E; Cofre R Sci Rep; 2020 Oct; 10(1):17725. PubMed ID: 33082424 [TBL] [Abstract][Full Text] [Related]
97. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Brandt SD; Kavanagh PV; Twamley B; Westphal F; Elliott SP; Wallach J; Stratford A; Klein LM; McCorvy JD; Nichols DE; Halberstadt AL Drug Test Anal; 2018 Feb; 10(2):310-322. PubMed ID: 28585392 [TBL] [Abstract][Full Text] [Related]
98. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Preller KH; Razi A; Zeidman P; Stämpfli P; Friston KJ; Vollenweider FX Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2743-2748. PubMed ID: 30692255 [TBL] [Abstract][Full Text] [Related]
99. Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. Marcher-Rørsted E; Halberstadt AL; Klein AK; Chatha M; Jademyr S; Jensen AA; Kristensen JL ACS Chem Neurosci; 2020 May; 11(9):1238-1244. PubMed ID: 32212672 [TBL] [Abstract][Full Text] [Related]